SEC Form	4							
F	ORM 4	UNITED S	TATES SECURITIES AND EXCHANGE CO	MMIS	SION			
			Washington, D.C. 20549					
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See			IENT OF CHANGES IN BENEFICIAL OWN	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5				
Instruction			Filed pursuant to Section 16(a) of the Securities Exchange Act of 193 or Section 30(h) of the Investment Company Act of 1940	4				
1. Name and Address of Reporting Person [*] Moran Kevin Patrick			2. Issuer Name and Ticker or Trading Symbol Vanda Pharmaceuticals Inc. [VNDA]		tionship of R all applicab	Reporting Person(s) to Issuer le)		
			winder Harmaceuteurs me. [(hbh]		Director		10% Owner	
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)		Officer (gi below)		Other (specify below)	
l` '	SYLVANIA AVENU	,	02/16/2023		SVP	P, CFO & Treasurer		
SUITE 3001	R							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 2. Transaction 2A. Deemed Execution Date 6. Ownership 7. Nature 1. Title of Security (Instr. 3) 5. Amount of Securities Beneficially Owned Following Form: Direct (D) or Indirect (I) (Instr. 4) of Indirect Beneficial Transaction (Month/Day/Year) 5) if any (Month/Day/Year) Code (Instr. 8) Ownership (Instr. 4) Reported Transaction(s) (Instr. 3 and 4) (A) or (D) Code v Price Amount Common Stock 02/16/2023 А 32,700(1) A **\$0.00** 152,860 D T Common Stock 635 By Wife

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	(eigi, pare, cane, manane, epiterio, contentioo)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$7.05	02/16/2023		A		77,500		(2)	02/15/2033	Common Stock	77,500	\$0.00	77,500	D	

Explanation of Responses:

1. Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2024, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.

2. The option vests with respect to 25% of the underlying shares on February 16, 2024, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date.

Remarks:

(Street)

(City)

WASHINGTON DC

(State)

/s/ Kevin Patrick Moran

0.5

6. Individual or Joint/Group Filing (Check Applicable

Form filed by One Reporting Person

02/21/2023

Date

Form filed by More than One Reporting

Line)

X

Person

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

20037

(Zip)

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.